Literature DB >> 25800755

Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.

Karen Dybkær1, Martin Bøgsted1, Steffen Falgreen1, Julie S Bødker1, Malene K Kjeldsen1, Alexander Schmitz1, Anders E Bilgrau1, Zijun Y Xu-Monette1, Ling Li1, Kim S Bergkvist1, Maria B Laursen1, Maria Rodrigo-Domingo1, Sara C Marques1, Sophie B Rasmussen1, Mette Nyegaard1, Michael Gaihede1, Michael B Møller1, Richard J Samworth1, Rajen D Shah1, Preben Johansen1, Tarec C El-Galaly1, Ken H Young1, Hans E Johnsen2.   

Abstract

PURPOSE: Current diagnostic tests for diffuse large B-cell lymphoma use the updated WHO criteria based on biologic, morphologic, and clinical heterogeneity. We propose a refined classification system based on subset-specific B-cell-associated gene signatures (BAGS) in the normal B-cell hierarchy, hypothesizing that it can provide new biologic insight and diagnostic and prognostic value. PATIENTS AND METHODS: We combined fluorescence-activated cell sorting, gene expression profiling, and statistical modeling to generate BAGS for naive, centrocyte, centroblast, memory, and plasmablast B cells from normal human tonsils. The impact of BAGS-assigned subtyping was analyzed using five clinical cohorts (treated with cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP], n = 270; treated with rituximab plus CHOP [R-CHOP], n = 869) gathered across geographic regions, time eras, and sampling methods. The analysis estimated subtype frequencies and drug-specific resistance and included a prognostic meta-analysis of patients treated with first-line R-CHOP therapy.
RESULTS: Similar BAGS subtype frequencies were assigned across 1,139 samples from five different cohorts. Among R-CHOP-treated patients, BAGS assignment was significantly associated with overall survival and progression-free survival within the germinal center B-cell-like subclass; the centrocyte subtype had a superior prognosis compared with the centroblast subtype. In agreement with the observed therapeutic outcome, centrocyte subtypes were estimated as being less resistant than the centroblast subtype to doxorubicin and vincristine. The centroblast subtype had a complex genotype, whereas the centrocyte subtype had high TP53 mutation and insertion/deletion frequencies and expressed LMO2, CD58, and stromal-1-signature and major histocompatibility complex class II-signature genes, which are known to have a positive impact on prognosis.
CONCLUSION: Further development of a diagnostic platform using BAGS-assigned subtypes may allow pathogenetic studies to improve disease management.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25800755      PMCID: PMC4397280          DOI: 10.1200/JCO.2014.57.7080

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  55 in total

Review 1.  Transcriptional networks in developing and mature B cells.

Authors:  Patrick Matthias; Antonius G Rolink
Journal:  Nat Rev Immunol       Date:  2005-06       Impact factor: 53.106

2.  CXCR4 expression functionally discriminates centroblasts versus centrocytes within human germinal center B cells.

Authors:  Gersende Caron; Simon Le Gallou; Thierry Lamy; Karin Tarte; Thierry Fest
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

3.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.

Authors:  Yasodha Natkunam; Shuchun Zhao; David Y Mason; Jun Chen; Behnaz Taidi; Margaret Jones; Anne S Hammer; Stephen Hamilton Dutoit; Izidore S Lossos; Ronald Levy
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

5.  Differential case reporting in a national clinical quality database: an analysis of the impact on comparison of outcome between departments.

Authors:  Solvej Mårtensson; Birgitte L Frederiksen; Peter De Nully Brown; Susanne Oksbjerg Dalton; Merete Osler
Journal:  Qual Manag Health Care       Date:  2012 Oct-Dec       Impact factor: 0.926

6.  R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group.

Authors:  A O Gang; C Strøm; M Pedersen; F d'Amore; L M Pedersen; A Bukh; B B Pedersen; M B Moeller; L S Mortensen; O V Gadeberg; S Ingeberg; T Mourits-Andersen; S Pulczynski; P d Nully Brown
Journal:  Ann Oncol       Date:  2011-04-02       Impact factor: 32.976

Review 7.  Pathogenesis of human B cell lymphomas.

Authors:  Arthur L Shaffer; Ryan M Young; Louis M Staudt
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

8.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

9.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

10.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

View more
  50 in total

1.  MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.

Authors:  Hanne Due; Anna Amanda Schönherz; Laura Ryø; Maria Nascimento Primo; Ditte Starberg Jespersen; Emil Aagaard Thomsen; Anne Stidholt Roug; Min Xiao; Xiaohong Tan; Yuyang Pang; Ken H Young; Martin Bøgsted; Jacob Giehm Mikkelsen; Karen Dybkær
Journal:  Blood Adv       Date:  2019-04-09

Review 2.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

3.  A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology.

Authors:  Thomas Yssing Michaelsen; Julia Richter; Rasmus Froberg Brøndum; Wolfram Klapper; Hans Erik Johnsen; Mads Albertsen; Karen Dybkær; Martin Bøgsted
Journal:  Blood Adv       Date:  2018-07-10

4.  Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.

Authors:  Qaid Ahmed Shagera; Gi Jeong Cheon; Youngil Koh; Min Young Yoo; Keon Wook Kang; Dong Soo Lee; E Edmund Kim; Sung-Soo Yoon; June-Key Chung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-02       Impact factor: 9.236

5.  Integrated analysis of 10 lymphoma datasets identifies E2F8 as a key regulator in Burkitt's lymphoma and mantle cell lymphoma.

Authors:  An-Ping Yang; Leyna G Liu; Min-Min Chen; Fang Liu; Hua You; Lian Liu; Hua Yang; Yang Xun; Jing Liu; Rui-Xue Wang; David D Brand; Dahai Liu; Song Guo Zheng; Wen-Xing Li
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

6.  Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Authors:  Zijun Y Xu-Monette; Ling Li; John C Byrd; Kausar J Jabbar; Ganiraju C Manyam; Charlotte Maria de Winde; Michiel van den Brand; Alexandar Tzankov; Carlo Visco; Jing Wang; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Ben M Parsons; Jane N Winter; Michael Wang; Frederick B Hagemeister; Miguel A Piris; J Han van Krieken; L Jeffrey Medeiros; Yong Li; Annemiek B van Spriel; Ken H Young
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

7.  Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Authors:  Y Xia; Z Y Xu-Monette; A Tzankov; X Li; G C Manyam; V Murty; G Bhagat; S Zhang; L Pasqualucci; C Visco; K Dybkaer; A Chiu; A Orazi; Y Zu; K L Richards; E D Hsi; W W L Choi; J H van Krieken; J Huh; M Ponzoni; A J M Ferreri; M B Møller; B M Parsons; J N Winter; M A Piris; J Westin; N Fowler; R N Miranda; C Y Ok; Y Li; J Li; L J Medeiros; K H Young
Journal:  Leukemia       Date:  2016-08-29       Impact factor: 11.528

8.  Cell of origin of transformed follicular lymphoma.

Authors:  Robert Kridel; Anja Mottok; Pedro Farinha; Susana Ben-Neriah; Daisuke Ennishi; Yvonne Zheng; Elizabeth A Chavez; Hennady P Shulha; King Tan; Fong Chun Chan; Merrill Boyle; Barbara Meissner; Adele Telenius; Laurie H Sehn; Marco A Marra; Sohrab P Shah; Christian Steidl; Joseph M Connors; David W Scott; Randy D Gascoyne
Journal:  Blood       Date:  2015-08-25       Impact factor: 22.113

9.  A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.

Authors:  Julie Støve Bødker; Rasmus Froberg Brøndum; Alexander Schmitz; Anna Amanda Schönherz; Ditte Starberg Jespersen; Mads Sønderkær; Charles Vesteghem; Hanne Due; Caroline Holm Nørgaard; Martin Perez-Andres; Mehmet Kemal Samur; Faith Davies; Brian Walker; Charlotte Pawlyn; Martin Kaiser; David Johnson; Uta Bertsch; Annemiek Broyl; Mark van Duin; Rajen Shah; Preben Johansen; Martin Agge Nørgaard; Richard J Samworth; Pieter Sonneveld; Hartmut Goldschmidt; Gareth J Morgan; Alberto Orfao; Nikhil Munshi; Hans Erik Johnson; Tarec El-Galaly; Karen Dybkær; Martin Bøgsted
Journal:  Blood Adv       Date:  2018-09-25

10.  Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.

Authors:  Zhiyu Liu; Zijun Y Xu-Monette; Xin Cao; Ganiraju C Manyam; Xiaoxiao Wang; Alexandar Tzankov; Yi Xia; Xin Li; Carlo Visco; Ruifang Sun; Li Zhang; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Ben M Parsons; Michael B Møller; Miguel A Piris; Jane N Winter; Dennis P O'Malley; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2015-08-07       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.